



FOR IMMEDIATE RELEASE ON October 21, 2025

Flamma Selected For 2025 CDMO Leadership Awards Europe

Chignolo D'Isola, Bergamo, Italy – October 21, 2025 – The **Flamma Group** (“Flamma”), a global, fully integrated company producing and commercializing small molecule Active Pharmaceutical Ingredients (APIs) for the life science industry as well as a preeminent Contract Development and Manufacturing Organization (CDMO) of New Chemical Entities (NCEs) and late stage intermediates for the Innovator Companies, is proud to announce that it has received a 2025 CDMO Leadership Award Europe that will be presented in Frankfurt on October 28, 2025.

Flamma has been recognized as a 2025 CDMO Leadership Awards Europe winner in the **Small Molecule API** category. Flamma is also a finalist for the **Champion Award** which will be announced during the rewards ceremony. The Champion Award recognizes the highest-scoring CDMO in each category. You can learn more at: <https://www.cmoleadershipawards.com/2025-cdmola-europe/>

“The entire Flamma team is truly honored to receive this award. After being honored earlier in the year in the Small Molecule API- Global category, this additional award shows the industry the commitment that Flamma has made to our customers,” noted Kenneth Drew, Ph.D., VP Flamma USA. “The Outsourced Pharma team goes to great lengths to provide a platform that recognizes excellence in the service side of the Biotech and Pharma industry. Flamma will always continue to work at an award winning level regardless. With that said, it is gratifying to be recognized for our efforts.”

“The 2025 CDMO Leadership Awards Europe is a well-deserved recognition to European organizations that have demonstrated excellence in contract development and manufacturing. These awards are the most important in our industry because they are based on the judgement of biopharma sponsors and the value they place in trusted partnerships,” according to Louis Garguilo, Chief Editor, Outsourced Pharma

Flamma will proudly accept the awards at the CDMO Leadership Awards Europe Ceremony and Reception on October 28, 2025 at the Steigenberger Frankfurter Hof in Frankfurt.



Contact Flamma

Kenneth Drew, Ph.D., VP Flamma USA

1-617-515-0975

ken.drew@flammagroup.com

About the CDMO Leadership Awards

The CDMO Leadership Awards are presented by Outsourced Pharma and Life Science Connect. Winners are selected based on primary research conducted by Orientation Marketing, reflecting direct feedback from biopharmaceutical professionals who have recently partnered with CDMOs. The awards recognize contract development and manufacturing organizations that deliver excellence in quality, capabilities, expertise, reliability, compatibility, and service. Learn more at www.cmoleadershipawards.com.

About Life Science Connect

Life Science Connect is a network of trusted online communities, including Clinical Leader, Outsourced Pharma, Bioprocess Online, Cell & Gene, and others, dedicated to helping industry professionals make informed decisions and build valuable partnerships. Through expert editorial content and innovative commercial solutions, LSC connects biopharma professionals with suppliers who can help advance development and manufacturing programs.

About Flamma:

The Flamma Group is a family-owned and operated **Contract Development and Manufacturing Organization (CDMO)** headquartered in Bergamo, near Milan in Northern Italy. Founded in 1950, Flamma has built a strong reputation as a fully integrated partner for the **development and cGMP manufacture of small molecule APIs** as well as NCEs, RSMs and advanced intermediates.

Flamma's fully integrated CDMO platform supports pharma and biotech clients across the entire drug development lifecycle from early-stage development through commercial manufacturing. In addition to its recognized leadership in small molecule manufacturing, Flamma brings deep expertise in high-value chiral technologies, including amino acids, small peptides produced via liquid-phase synthesis and specialty phosphoramidites. This combination of broad capabilities and specialized knowledge allows Flamma to deliver reliable, efficient, and tailored solutions to pharmaceutical, nutraceutical, and cosmetic partners worldwide.

Flamma manages its **cGMP manufacturing facilities strategically across Italy** (Chignolo, Isso, Bulciago), **China** (Dalian), and the **USA** (Malvern, PA). Our sites are inspected by regulatory agencies therefore offering a trusted and cost-effective production with transparent supply chain security. Our Flamma USA site supports early-



phase development along with HPAPI manufacturing, ensuring proximity and responsiveness to North American clients.

With a team of over 1,000 professionals along with reactor capacity of 1,300 m³, Flamma ensures the agility, dependability and scale required to accelerate the time to market for customer compounds while maintaining the highest standards of quality, safety and sustainability compliance.

FLAMMA - THE THINKING CDMO™.

<https://www.flammagroup.com/>

<https://www.linkedin.com/company/flamma-spa/>

<https://twitter.com/flammagroup>

<https://www.facebook.com/TheFlammaGroup/>